Therapy for myeloproliferative neoplasms: when, which agent, and how?
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Therapy for myeloproliferative neoplasms: when, which agent, and how?
Authors
Keywords
-
Journal
BLOOD
Volume 124, Issue 24, Pages 3529-3537
Publisher
American Society of Hematology
Online
2014-12-04
DOI
10.1182/blood-2014-05-577635
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Distinct clustering of symptomatic burden among myeloproliferative neoplasm patients: retrospective assessment in 1470 patients
- (2014) H. L. Geyer et al. BLOOD
- CALR and ASXL1 mutations-based molecular prognostication in primary myelofibrosis: an international study of 570 patients
- (2014) A Tefferi et al. LEUKEMIA
- Type 1 vs type 2 calreticulin mutations in primary myelofibrosis: differences in phenotype and prognostic impact
- (2014) A Tefferi et al. LEUKEMIA
- JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes
- (2013) E. Rumi et al. BLOOD
- Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial
- (2013) H. Gisslinger et al. BLOOD
- Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon -2a
- (2013) A. Quintas-Cardama et al. BLOOD
- A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea
- (2013) Srdan Verstovsek et al. CANCER
- Combination treatment for myeloproliferative neoplasms using JAK and pan-class I PI3K inhibitors
- (2013) Meng Ling Choong et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study
- (2013) A Tefferi et al. LEUKEMIA
- Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis
- (2013) A Pardanani et al. LEUKEMIA
- Significance of cytogenetic abnormalities in patients with polycythemia vera
- (2013) Matjaz Sever et al. LEUKEMIA & LYMPHOMA
- Somatic CALR Mutations in Myeloproliferative Neoplasms with Nonmutated JAK2
- (2013) J. Nangalia et al. NEW ENGLAND JOURNAL OF MEDICINE
- Somatic Mutations of Calreticulin in Myeloproliferative Neoplasms
- (2013) Thorsten Klampfl et al. NEW ENGLAND JOURNAL OF MEDICINE
- Non-cell-autonomous hedgehog signaling promotes murine B lymphopoiesis from hematopoietic progenitors
- (2012) C. L. Cooper et al. BLOOD
- A prognostic model to predict survival in 867 World Health Organization-defined essential thrombocythemia at diagnosis: a study by the International Working Group on Myelofibrosis Research and Treatment
- (2012) F. Passamonti et al. BLOOD
- Leucocytosis and thrombosis at diagnosis are associated with poor survival in polycythaemia vera: a population-based study of 327 patients
- (2012) Gilles Bonicelli et al. BRITISH JOURNAL OF HAEMATOLOGY
- The HDAC inhibitor Givinostat modulates the hematopoietic transcription factors NFE2 and C-MYB in JAK2V617F myeloproliferative neoplasm cells
- (2012) Ariel Amaru Calzada et al. EXPERIMENTAL HEMATOLOGY
- Myeloproliferative Neoplasm (MPN) Symptom Assessment Form Total Symptom Score: Prospective International Assessment of an Abbreviated Symptom Burden Scoring System Among Patients With MPNs
- (2012) Robyn M. Emanuel et al. JOURNAL OF CLINICAL ONCOLOGY
- Allogeneic stem cell transplantation for myeloproliferative neoplasm in blast phase
- (2012) Chad Cherington et al. LEUKEMIA RESEARCH
- A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis
- (2012) Srdan Verstovsek et al. NEW ENGLAND JOURNAL OF MEDICINE
- JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis
- (2012) Claire Harrison et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cardiovascular Events and Intensity of Treatment in Polycythemia Vera
- (2012) Roberto Marchioli et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1/2 study in patients with myelofibrosis
- (2011) P. Guglielmelli et al. BLOOD
- The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): International Prospective Validation and Reliability Trial in 402 patients
- (2011) R. Scherber et al. BLOOD
- Philadelphia-Negative Classical Myeloproliferative Neoplasms: Critical Concepts and Management Recommendations From European LeukemiaNet
- (2011) Tiziano Barbui et al. JOURNAL OF CLINICAL ONCOLOGY
- Survival and Disease Progression in Essential Thrombocythemia Are Significantly Influenced by Accurate Morphologic Diagnosis: An International Study
- (2011) Tiziano Barbui et al. JOURNAL OF CLINICAL ONCOLOGY
- Treatment of Polycythemia Vera With Hydroxyurea and Pipobroman: Final Results of a Randomized Trial Initiated in 1980
- (2011) Jean-Jacques Kiladjian et al. JOURNAL OF CLINICAL ONCOLOGY
- Lenalidomide and prednisone for myelofibrosis: Eastern Cooperative Oncology Group (ECOG) phase 2 trial E4903
- (2010) R. A. Mesa et al. BLOOD
- correspondence: Incidence of leukaemia in patients with primary myelofibrosis and RBC-transfusion-dependence
- (2010) Francesco Passamonti et al. BRITISH JOURNAL OF HAEMATOLOGY
- Thrombosis in myelofibrosis: prior thrombosis is the only predictive factor and most venous events are provoked
- (2010) M. A. Elliott et al. HAEMATOLOGICA
- DIPSS Plus: A Refined Dynamic International Prognostic Scoring System for Primary Myelofibrosis That Incorporates Prognostic Information From Karyotype, Platelet Count, and Transfusion Status
- (2010) Naseema Gangat et al. JOURNAL OF CLINICAL ONCOLOGY
- Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1
- (2010) A Tefferi LEUKEMIA
- Thrombosis in primary myelofibrosis: incidence and risk factors
- (2009) T. Barbui et al. BLOOD
- A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment)
- (2009) F. Passamonti et al. BLOOD
- The natural history and treatment outcome of blast phase BCR-ABL- myeloproliferative neoplasms
- (2008) C. S. Tam et al. BLOOD
- Characteristics and clinical correlates of MPL 515W>L/K mutation in essential thrombocythemia
- (2008) A. M. Vannucchi et al. BLOOD
- New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment
- (2008) F. Cervantes et al. BLOOD
- Risk factors for leukemic transformation in patients with primary myelofibrosis
- (2008) Jocelin Huang et al. CANCER
- Prognostic factors for thrombosis, myelofibrosis, and leukemia in essential thrombocythemia: a study of 605 patients
- (2008) F. Passamonti et al. HAEMATOLOGICA
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started